ANI Pharmaceuticals Inc
ANIP
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.81B
Close$
$-54.62
167.8% downside
Current Fair Value
167.8% downsideOvervalued by 167.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.81 Billion |
|---|---|
| Enterprise Value | $1.83 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $3.5 |
| Beta | 0.44 |
| Outstanding Shares | 20,914,000 |
Return
| Return on Equity | 16.68% |
|---|---|
| Return on Assets | 6.60% |
| Return on Invested Capital | 11.72% |
Valuation & Multiples
| P/E Ratio | 19.34 |
|---|---|
| PEG | 21.96 |
| Price to Sales | 1.83 |
| Price to Book Ratio | 3.1 |
| Enterprise Value to Revenue | 1.98 |
| Enterprise Value to EBIT | 13.2 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.59 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 8, 2026
EPS Estimate
$1.28
Average shareholder expectationRevenue Estimate
$207.63 M
Average shareholder expectationNext Earnings Call
Expected Date
August 14, 2026
EPS Estimate
$2.01
Average shareholder expectationRevenue Estimate
$262.14 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.0612▼ 18.14% |
|---|---|
| Total Calls | 202,500▲ 42.01% |
| Total Puts | 417,400▲ 30.52% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 116.63%▲ 11.19% |
|---|---|
| Total Invested | $1.80B▲ 7.58% |
| Investors Holding | 286▼ 7.00% |
ESG Score
No data
About ANI Pharmaceuticals Inc
CEO: Patrick Walsh ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include ...